150 related articles for article (PubMed ID: 7912166)
1. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
[TBL] [Abstract][Full Text] [Related]
2. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
3. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
[TBL] [Abstract][Full Text] [Related]
4. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
5. Shared T cell epitopes in epithelial tumors.
Peoples GE; Smith RC; Linehan DC; Yoshino I; Goedegebuure PS; Eberlein TJ
Cell Immunol; 1995 Sep; 164(2):279-86. PubMed ID: 7656335
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
[TBL] [Abstract][Full Text] [Related]
7. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.
Ioannides CG; Fisk B; Fan D; Biddison WE; Wharton JT; O'Brian CA
Cell Immunol; 1993 Oct; 151(1):225-34. PubMed ID: 7691418
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
11. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
[TBL] [Abstract][Full Text] [Related]
12. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
13. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
14. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro.
Fisk B; Chesak B; Pollack MS; Wharton JT; Ioannides CG
Cell Immunol; 1994 Sep; 157(2):415-27. PubMed ID: 7915203
[TBL] [Abstract][Full Text] [Related]
15. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
17. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
[TBL] [Abstract][Full Text] [Related]
18. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
19. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient.
Nagata Y; Hanagiri T; Takenoyama M; Fukuyama T; Mizukami M; So T; Ichiki Y; Sugaya M; Sugio K; Yasumoto K
Clin Cancer Res; 2005 Jul; 11(14):5265-72. PubMed ID: 16033845
[TBL] [Abstract][Full Text] [Related]
20. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]